e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
New data on established treatments for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Baseline symptom scores and future risk of severe exacerbation: The SPARK study
Wisia Wedzicha (London, United Kingdom), Jadwiga A. Wedzicha, Karen Mezzi, Robert Fogel, Donald Banerji
Source:
International Congress 2015 – New data on established treatments for asthma and COPD
Session:
New data on established treatments for asthma and COPD
Session type:
Thematic Poster Session
Number:
1006
Disease area:
Airway diseases
Abstract
Introduction
The SPARK study evaluated the effect of the dual bronchodilator, QVA149 (fixed-dose combination of indacaterol and glycopyrronium) versus the LAMAs glycopyrronium and tiotropium, on exacerbations (EXB) in patients (pts) with severe-to-very severe COPD.
Methods
This 64-week, multicentre, double-blind study randomised 2224 pts with severe-to-very severe COPD and a history of
³
1 EXB in previous year. Here, we compared the baseline daily symptom scores in pts with
³
1 severe EXB (n=248),
³
1 mild-moderate EXB (n=1628) and no EXB (n=306) during the study.
Results
Baseline symptoms score in pts with
³
1 severe EXB, with
³
1 mild-moderate EXB and with no EXB was 8.57, 7.54 and 7.18, respectively. Baseline symptom score was significantly higher in pts with
³
1 severe EXB compared with pts with
³
1 mild-moderate EXB and pts with no EXB (LSM differences: 1.39 and 1.13, respectively; both p<0.0001). Many individual symptoms including dyspnoea, cough, wheeze and sputum were also significantly different (Figure). There was no difference in the symptoms of fever, cold and sputum colour.
Conclusions
In the 1-year SPARK study, patients experiencing severe exacerbations appear to have more severe baseline symptom burden, and specifically dyspnoea, even compared to those with mild or moderate exacerbations. A high level of daily symptom burden may thus reflect a group of patients who should be carefully followed for risk of severe exacerbations.
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Wisia Wedzicha (London, United Kingdom), Jadwiga A. Wedzicha, Karen Mezzi, Robert Fogel, Donald Banerji. Baseline symptom scores and future risk of severe exacerbation: The SPARK study. Eur Respir J 2015; 46: Suppl. 59, 1006
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
The relation of comorbidities with the exacerbation severity in patients with COPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Usefulness of severity predictive scores in COPD exacerbations in hospitalized patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Comparing the prevalence of depression and anxiety in patients admitted with an exacerbation of COPD using two scoring systems
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Comparison of COPD patients with high and low symptoms from a real-world US survey
Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases
Year: 2015
Can we personalize COPD treatment by exacerbation frequency and severity? Three years of follow-up
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Assessing COPD profiles and outcomes by dyspnoea severity
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
The impact of comorbidities on the short-term serious health outcomes in hospitalized COPD patients due to exacerbation
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Impact of age-related comorbidities on the risk of COPD exacerbations in subjects with severe airflow limitation: A pan-European study
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Symptom profile of exacerbations in earlier and later COPD
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013
Mortality and readmissions in patients with severe COPD. Validation of the CODEX index
Source: International Congress 2015 – Best abstracts in COPD management
Year: 2015
Impact of comorbidities in COPD prognosys scores
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
LATE-BREAKING ABSTRACT: The prevalence of night and morning symptoms in primary care COPD patients: How do they relate to COPD health status and disease severity? An UNLOCK study
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
Gender differences in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Risk factors for another hospitalization in COPD patients hospitalized for exacerbation
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
COPD: Influence of patients’ nutritive status on the exacerbations rate
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept